Page 147 - CW E-Magazine (27-5-2025)

News from Abroad

GLOBAL PARTNERSHIP
Asahi Kasei arm and PeptiSystems join hands

to offer peptide manufacturing solutions

Asahi Kasei Bioprocess America
(AKBA) and Sweden’s PeptiSystems
have announced an exclusive partner-
ship aimed at delivering a streamlined
process to the peptide manufacturing
industry.

This collaboration establishes
AKBA as the exclusive OEM for pep-
tide synthesis columns to PeptiSys-
tems, which carries out R&D, manu-
facturing, and supply of instruments
used to synthesise peptide and oligo-
nucleotide therapeutics.

Asahi Kasei Bioprocess America
is part of the Asahi Kasei Life Science
operating segment, encompassing
the organisation’s purification, fluid
management, biosafety, and biologics
development and manufacturing
divisions.

The partnership combines AKBA’s
knowledge and product expertise with
PeptiSystems’ synthesisers.
Kasei’s columns adhere to that mantra systems, we are building foundational
Asahi Kasei Bioprocess America by providing our systems with maxi- technologies that deliver value to our
will supply PeptiSystems, with their mum flexibility and control.” customers.”
patented THESYS ACS Ergo design,
which will be optimised for peptide The partnership will extend glob- This announcement closely follows
processing. Unveiled in 2024, this ally across all relevant markets, such a notice regarding the operational start
column offers drastically reduced as drug and contract manufacturing. of Asahi Kasei Life Sciences, under
changeover time between batches Based on flow-through chemistry and which the company’s bioprocess divi-
without compromising user safety and solid support, the companies anticipate sion will operate.
product quality. this will bring evolutionary means for
peptide processing to the industry and In addition to Asahi Kasei Bio-
Together, the companies can offer their customers. process America, Asahi Kasei Life
a robust synthesis process that utilises Sciences includes Planova and Micro-
AKBA’s columns and PeptiSystems’ Mr. Chris Rombach, President of filters BioOptimal, its contract
peptide flow through synthesis systems. AKBA, stated, “This partnership is research organisation (CRO) testing
a natural next step as we expand our services performed by ViruSure of
Mr. Karin Granath, CEO of Pepti- presence in the TIDES market. By Austria, Bionique Testing Laborato-
Systems, said, “PeptiSystems has aligning our column expertise with ries, and a biologics CDMO, Bionova
always put chemistry first, and Asahi PeptiSystems’ innovative synthesis Scientific.

Chemical Weekly May 27, 2025 147

Contents Index to Advertisers Index to Products Advertised